Imunon Inc Financials
This page shows Imunon Inc (IMNN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing still underwrites research-driven operations, even as FY2025 showed a smaller but still material cash burn.
Liquidity improved for a reason the income statement does not show: operating cash burn narrowed from$19.0M in FY2024 to$13.9M in FY2025, yet cash still rose to$8.8M only because financing brought in$17.1M . That mix of lower burn and continued dependence on outside capital says the operating model is becoming leaner, not self-funding.
Capital intensity is low: FY2025 capex was only
Expense structure is concentrated in development spending: R&D of
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Imunon Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Imunon Inc carries a low D/E ratio of 0.74, meaning only $0.74 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 87/100, indicating a strong balance sheet with room for future borrowing.
Imunon Inc's current ratio of 2.32 indicates adequate short-term liquidity, earning a score of 43/100. The company can meet its near-term obligations, though with limited headroom.
Imunon Inc generates a 205.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -438.7% the prior year.
Imunon Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Imunon Inc generates $-0.96 in operating cash flow (-$13.9M OCF vs $14.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Imunon Inc's EBITDA was -$14.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 24.0% from the prior year.
Imunon Inc reported $14.5M in net income in fiscal year 2025. This represents an increase of 177.8% from the prior year.
Imunon Inc earned $-6.83 per diluted share (EPS) in fiscal year 2025. This represents an increase of 59.7% from the prior year.
Cash & Balance Sheet
Imunon Inc generated -$14.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 24.9% from the prior year.
Imunon Inc held $8.8M in cash against $0 in long-term debt as of fiscal year 2025.
Imunon Inc had 3M shares outstanding in fiscal year 2025. This represents an increase of 253.7% from the prior year.
Margins & Returns
Imunon Inc's ROE was 205.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 644.0 percentage points from the prior year.
Capital Allocation
Imunon Inc invested $7.8M in research and development in fiscal year 2025. This represents a decrease of 33.2% from the prior year.
Imunon Inc invested $281K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 849.8% from the prior year.
IMNN Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $2.3M | N/A | $1.9M+54.8% | $1.2M-43.3% | $2.2M | N/A | $3.3M+16.8% | $2.8M |
| SG&A Expenses | $2.0M | N/A | $1.6M+2.3% | $1.5M-22.2% | $2.0M | N/A | $1.7M-24.0% | $2.2M |
| Operating Income | -$4.3M | N/A | -$3.5M-25.6% | -$2.8M+33.2% | -$4.1M | N/A | -$5.0M+1.0% | -$5.0M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$4.2M | N/A | -$3.4M-25.1% | -$2.7M+33.2% | -$4.1M | N/A | -$4.8M-1.2% | -$4.8M |
| EPS (Diluted) | $-0.84 | N/A | $-1.16+46.0% | $-2.15 | $-3.15 | N/A | $-3.76+50.8% | $-7.64 |
IMNN Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.0M-34.7% | $12.3M+36.7% | $9.0M+2.3% | $8.8M+28.1% | $6.9M-29.4% | $9.7M-32.5% | $14.4M+48.5% | $9.7M |
| Current Assets | $6.6M-38.3% | $10.7M+47.8% | $7.3M+5.3% | $6.9M+35.3% | $5.1M-36.4% | $8.0M-36.1% | $12.5M+63.9% | $7.6M |
| Cash & Equivalents | $4.8M-45.4% | $8.8M+67.2% | $5.3M+11.0% | $4.7M+64.7% | $2.9M-51.1% | $5.9M-43.0% | $10.3M+94.3% | $5.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | $0 | N/A | N/A | N/A | $0 | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $4.7M-10.9% | $5.2M+6.5% | $4.9M-19.9% | $6.1M-4.4% | $6.4M+17.1% | $5.5M-11.7% | $6.2M+4.2% | $6.0M |
| Current Liabilities | $4.2M-9.9% | $4.6M+10.1% | $4.2M-21.1% | $5.3M-8.3% | $5.8M+21.1% | $4.8M-12.0% | $5.4M+7.2% | $5.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $3.4M-52.4% | $7.1M+73.0% | $4.1M+53.5% | $2.7M+488.4% | $452K-89.3% | $4.2M-48.2% | $8.2M+119.0% | $3.7M |
| Retained Earnings | -$425.5M-1.0% | -$421.3M-1.0% | -$417.1M-0.8% | -$413.6M-0.7% | -$410.9M-1.0% | -$406.8M-1.0% | -$402.7M-1.2% | -$397.9M |
IMNN Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.0M-9.0% | -$3.7M+17.7% | -$4.4M-50.5% | -$3.0M-3.7% | -$2.8M+35.6% | -$4.4M-9.0% | -$4.1M+10.0% | -$4.5M |
| Capital Expenditures | $260K+7134.7% | $4K | $0-100.0% | $17K-93.3% | $260K+1641.8% | $15K+417.8% | $3K | $0 |
| Free Cash Flow | -$4.2M-16.0% | -$3.7M+17.6% | -$4.4M-49.6% | -$3.0M+4.4% | -$3.1M+30.0% | -$4.4M-9.3% | -$4.1M+9.9% | -$4.5M |
| Investing Cash Flow | -$260K-7134.7% | -$4K | $0+100.0% | -$17K+93.3% | -$260K-1641.8% | -$15K-417.8% | -$3K-100.0% | $7.5M |
| Financing Cash Flow | -$2K-100.0% | $7.2M+44.9% | $5.0M+2.8% | $4.8M+4465.9% | $106K+3325.3% | -$3K | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
IMNN Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -126.5% | N/A | -84.0%+19.0pp | -103.0%+804.5pp | -907.6% | N/A | -59.2%+68.8pp | -128.0% |
| Return on Assets | -53.0% | N/A | -38.1%-7.0pp | -31.2%+28.6pp | -59.8% | N/A | -33.7%+15.7pp | -49.4% |
| Current Ratio | 1.59-0.7 | 2.32+0.6 | 1.73+0.4 | 1.30+0.4 | 0.88-0.8 | 1.67-0.6 | 2.30+0.8 | 1.51 |
| Debt-to-Equity | 1.39+0.6 | 0.74-0.5 | 1.20-1.1 | 2.30-11.9 | 14.18+12.9 | 1.29+0.5 | 0.76-0.8 | 1.59 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Imunon Inc profitable?
Yes, Imunon Inc (IMNN) reported a net income of $14.5M in fiscal year 2025.
What is Imunon Inc's EBITDA?
Imunon Inc (IMNN) had EBITDA of -$14.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Imunon Inc's return on equity (ROE)?
Imunon Inc (IMNN) has a return on equity of 205.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Imunon Inc's free cash flow?
Imunon Inc (IMNN) generated -$14.2M in free cash flow during fiscal year 2025. This represents a 24.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Imunon Inc's operating cash flow?
Imunon Inc (IMNN) generated -$13.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Imunon Inc's total assets?
Imunon Inc (IMNN) had $12.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Imunon Inc's capital expenditures?
Imunon Inc (IMNN) invested $281K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Imunon Inc spend on research and development?
Imunon Inc (IMNN) invested $7.8M in research and development during fiscal year 2025.
What is Imunon Inc's current ratio?
Imunon Inc (IMNN) had a current ratio of 2.32 as of fiscal year 2025, which is generally considered healthy.
What is Imunon Inc's debt-to-equity ratio?
Imunon Inc (IMNN) had a debt-to-equity ratio of 0.74 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Imunon Inc's return on assets (ROA)?
Imunon Inc (IMNN) had a return on assets of 118.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Imunon Inc's cash runway?
Based on fiscal year 2025 data, Imunon Inc (IMNN) had $8.8M in cash against an annual operating cash burn of $13.9M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Imunon Inc's Piotroski F-Score?
Imunon Inc (IMNN) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Imunon Inc's earnings high quality?
Imunon Inc (IMNN) has an earnings quality ratio of -0.96x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Imunon Inc?
Imunon Inc (IMNN) scores 22 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.